Roux-en-Y Gastric Bypass Shows Continued Diabetes Remission Despite Weight Recurrence

Roux-en-Y gastric bypass (RYGB) patients display higher rates of continued diabetes remission (CDR) compared to sleeve gastrectomy (SG) patients, even with weight recurrence (WR). The odds of Type 2 diabetes mellitus (T2DM) recurrence were 5.5 times higher in the SG group. Baseline insulin use, higher preoperative HbA1c, and longer preoperative T2DM duration were associated with T2DM recurrence, while WR was not. RYGB provides weight-loss independent metabolic benefits likely due to bypassing the proximal small-intestine.